Climb Bio Valuation
| CLYM Stock | 1.51 0.05 3.42% |
Based on Macroaxis valuation methodology, the firm appears to be undervalued. Climb Bio shows a prevailing Real Value of USD3.55 per share. The current price of the firm is USD1.51. Our model approximates the value of Climb Bio from analyzing the firm fundamentals such as Current Valuation of (11.77 M), return on equity of -0.62, and Shares Owned By Insiders of 7.95 % as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Climb Bio's valuation include:
Undervalued
Today
Please note that Climb Bio's price fluctuation is unstable at this time. Calculation of the real value of Climb Bio is based on 3 months time horizon. Increasing Climb Bio's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Climb stock is determined by what a typical buyer is willing to pay for full or partial control of Climb Bio. Since Climb Bio is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Climb Stock. However, Climb Bio's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.51 | Real 3.55 | Target 10.0 | Hype 1.51 | Naive 1.61 |
The intrinsic value of Climb Bio's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Climb Bio's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Climb Bio helps investors to forecast how Climb stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Climb Bio more accurately as focusing exclusively on Climb Bio's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Climb Bio's intrinsic value based on its ongoing forecasts of Climb Bio's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Climb Bio's closest peers.
Climb Bio Cash |
|
Climb Valuation Trend
Knowing Climb Bio's actual value is paramount for traders when making sound investment determinations. Using both Climb Bio's enterprise value as well as its market capitalization is the best way to estimate the value of the company and is usually enough for investors to make market timing decisions.
Climb Bio Total Value Analysis
Climb Bio is currently anticipated to have valuation of (11.77 M) with market capitalization of 85.82 M, debt of 532 K, and cash on hands of . The negative valuation of Climb Bio may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Climb Bio fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(11.77 M) | 85.82 M | 532 K |
Climb Bio Asset Utilization
One of the ways to look at asset utilization of Climb is to check how much profit was generated for every dollar of assets it reports. Climb Bio shows a negative utilization of assets of -0.19 percent, losing USD0.001895 for each dollar of assets held by the firm. Inadequate asset utilization signifies that the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of Climb Bio shows how discouraging it operates for each dollar spent on its assets.Climb Bio Ownership Allocation
Climb Bio holds a total of 67.58 Million outstanding shares. The majority of Climb Bio outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Climb Bio to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Climb Bio. Please pay attention to any change in the institutional holdings of Climb Bio as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Climb Bio Profitability Analysis
Net Loss for the year was (73.9 M) with profit before overhead, payroll, taxes, and interest of 0.About Climb Bio Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Climb Bio. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Climb Bio based exclusively on its fundamental and basic technical indicators. By analyzing Climb Bio's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Climb Bio's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Climb Bio. We calculate exposure to Climb Bio's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Climb Bio's related companies.Climb Bio Growth Indicators
Investing in growth stocks can be very risky. If the company such as Climb Bio does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 48.2 M |
Climb Bio Current Valuation Indicators
Climb Bio's valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Climb Bio's valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Climb Bio, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Climb Bio's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Climb Bio's worth.When determining whether Climb Bio is a strong investment it is important to analyze Climb Bio's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Climb Bio's future performance. For an informed investment choice regarding Climb Stock, refer to the following important reports: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Climb Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. To learn how to invest in Climb Stock, please use our How to Invest in Climb Bio guide.You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Climb Bio. If investors know Climb will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Climb Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Climb Bio is measured differently than its book value, which is the value of Climb that is recorded on the company's balance sheet. Investors also form their own opinion of Climb Bio's value that differs from its market value or its book value, called intrinsic value, which is Climb Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Climb Bio's market value can be influenced by many factors that don't directly affect Climb Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Climb Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Climb Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Climb Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.